tiprankstipranks
Advertisement
Advertisement

AKBA Stock Latest News

Akebia Shareholders Approve Governance Measures and Share Increase
Company AnnouncementsAkebia Shareholders Approve Governance Measures and Share Increase
6d ago
8K
AKBA
Akebia announces new Vafseo patent
PremiumThe Fly
Akebia announces new Vafseo patent
18d ago
AKBA
Akebia Therapeutics Earnings Call: Vafseo Drives Transition
PremiumCompany Announcements
Akebia Therapeutics Earnings Call: Vafseo Drives Transition
1M ago
AKBA
Akebia Therapeutics Balances Vafseo Momentum With Headwinds
PremiumCompany Announcements
Akebia Therapeutics Balances Vafseo Momentum With Headwinds
2M ago
AKBA
Akebia reports Q1 EPS (3c), consensus 0c
PremiumThe Fly
Akebia reports Q1 EPS (3c), consensus 0c
2M ago
AKBA
Is AKBA a Buy, Before Earnings?
PremiumPre-EarningsIs AKBA a Buy, Before Earnings?
2M ago
AKBA
Akebia doses first participants in AKB-9090 trial
Premium
The Fly
Akebia doses first participants in AKB-9090 trial
3M ago
AKBA
Akebia (AKBA): Buy Rating Backed by Vafseo Momentum and High-Value Renal Pipeline Upside
Premium
Ratings
Akebia (AKBA): Buy Rating Backed by Vafseo Momentum and High-Value Renal Pipeline Upside
3M ago
AKBA
Akebia Therapeutics Earnings Call: Vafseo Drives Growth
PremiumCompany Announcements
Akebia Therapeutics Earnings Call: Vafseo Drives Growth
4M ago
AKBA
3 Best Stocks to Buy Today with 125%+ Upside, 2/27/2026, According to Top Analysts
PremiumMarket News
3 Best Stocks to Buy Today with 125%+ Upside, 2/27/2026, According to Top Analysts
4M ago
AKBA
BDSX
Akebia reports Q4 EPS (5c), consensus (4c)
PremiumThe Fly
Akebia reports Q4 EPS (5c), consensus (4c)
4M ago
AKBA
Akebia price target lowered to $4 from $5 at BTIG
PremiumThe Fly
Akebia price target lowered to $4 from $5 at BTIG
4M ago
AKBA
Akebia Therapeutics (AKBA) Q4 Earnings Cheat Sheet
PremiumPre-EarningsAkebia Therapeutics (AKBA) Q4 Earnings Cheat Sheet
4M ago
AKBA
Akebia’s Praliciguat FSGS Trial Moves Forward, Adding Optionality to the Kidney Pipeline
Premium
Company Announcements
Akebia’s Praliciguat FSGS Trial Moves Forward, Adding Optionality to the Kidney Pipeline
5M ago
AKBA
Akebia price target lowered to $4 from $6 at Piper Sandler
Premium
The Fly
Akebia price target lowered to $4 from $6 at Piper Sandler
5M ago
AKBA
Akebia Therapeutics Updates Executive Severance and Leadership Terms
PremiumCompany Announcements
Akebia Therapeutics Updates Executive Severance and Leadership Terms
5M ago
8K
AKBA
Akebia announces corporate updates, 2026 pipeline outlook
PremiumThe Fly
Akebia announces corporate updates, 2026 pipeline outlook
6M ago
AKBA
Akebia Therapeutics Outlines 2026 Vafseo Strategy and Pipeline
PremiumCompany Announcements
Akebia Therapeutics Outlines 2026 Vafseo Strategy and Pipeline
6M ago
8K
AKBA
Akebia Therapeutics: Advancing Praliciguat in FSGS and Vafseo Commercial Ramp Support Compelling Buy Thesis
PremiumRatings
Akebia Therapeutics: Advancing Praliciguat in FSGS and Vafseo Commercial Ramp Support Compelling Buy Thesis
6M ago
AKBA
Akebia announces first patient dosed in Phase 2 trial of praliciguat
PremiumThe FlyAkebia announces first patient dosed in Phase 2 trial of praliciguat
6M ago
AKBA
Strategic Expansion and Market Potential Drive Buy Rating for Akebia Therapeutics
Premium
Ratings
Strategic Expansion and Market Potential Drive Buy Rating for Akebia Therapeutics
7M ago
AKBA
Akebia Therapeutics Acquires Global Rights to ADX-097
Premium
Company Announcements
Akebia Therapeutics Acquires Global Rights to ADX-097
7M ago
8K
AKBA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >